Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is positioned for success with its innovative pipeline of cell-based therapies, particularly OpRegen which has shown positive data in the treatment of AMD, a large unmet need in the medical community. Partnering with Roche and Genentech lends support and credibility to the potential of these therapies, and the company's proprietary AlloSCOPE platform provides a strong foundation for commercialization and scalability. Meanwhile, the reported improvements in visual and anatomical measures demonstrate the potential for meaningful disease stabilization and functional improvement in a historically irreversible condition, positioning Lineage Cell Therapeutics as a frontrunner in the biotechnology space.

Bears say

Lineage Cell Therapeutics is facing several risk factors, including clinical, regulatory, financial, commercial, legal, and market share risks, which could all potentially impact the success of their pipeline programs and overall financial performance. The company's AlloSCOPE manufacturing platform and TAI formulation may offer some potential advantages, but they have not yet been proven to be more effective than traditional cell therapy methods. Additionally, the company's current financial stability and market share are uncertain, especially given the volatility of the biotechnology industry.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.